6547 Stock Overview
A biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Medigen Vaccine Biologics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$55.00 |
| 52 Week High | NT$57.00 |
| 52 Week Low | NT$33.70 |
| Beta | 1.06 |
| 1 Month Change | 16.65% |
| 3 Month Change | 56.47% |
| 1 Year Change | 3.77% |
| 3 Year Change | -68.93% |
| 5 Year Change | 86.41% |
| Change since IPO | 158.90% |
Recent News & Updates
Shareholder Returns
| 6547 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 4.0% | 2.2% | 1.1% |
| 1Y | 3.8% | 13.1% | 8.8% |
Return vs Industry: 6547 underperformed the TW Biotechs industry which returned 13.1% over the past year.
Return vs Market: 6547 underperformed the TW Market which returned 17.2% over the past year.
Price Volatility
| 6547 volatility | |
|---|---|
| 6547 Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.7% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6547's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 6547's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | Leo Lee | www.medigenvac.com |
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respiratory syncytial virus (RSV), which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19.
Medigen Vaccine Biologics Corporation Fundamentals Summary
| 6547 fundamental statistics | |
|---|---|
| Market cap | NT$18.08b |
| Earnings (TTM) | -NT$80.46m |
| Revenue (TTM) | NT$605.64m |
29.9x
P/S Ratio-224.7x
P/E RatioIs 6547 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6547 income statement (TTM) | |
|---|---|
| Revenue | NT$605.64m |
| Cost of Revenue | NT$209.22m |
| Gross Profit | NT$396.42m |
| Other Expenses | NT$476.89m |
| Earnings | -NT$80.46m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 65.46% |
| Net Profit Margin | -13.29% |
| Debt/Equity Ratio | 0.6% |
How did 6547 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/22 18:58 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medigen Vaccine Biologics Corporation is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hsuan Chen | KGI Securities Co. Ltd. |
| Yijun Chen | SinoPac Securities Investment Service |